Why BIND Therapeutics (BIND) Stock Is Falling In After-Hours Trading Today

NEW YORK (TheStreet) -- BIND Therapeutics (BIND) shares are down -15.84% to $10.84 after the bell on Wednesday after the nanomedicine platform company and Amgen (AMGN) announced that they would not be exercising their collaborative option to develop an Accurin incorporating the Amgen therapeutic payload.

"The goal of this research collaboration was to optimize a specific therapeutic payload from Amgen. Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward and both collaborators have agreed that the program will not be continued," said BIND CEO Scott Minick.

Must ReadWarren Buffett's 25 Favorite Stocks

If you liked this article you might like

Bind Therapeutics (BIND) Strong On High Relative Volume Today

Bind Therapeutics (BIND) Weak On High Volume

5 Stocks Under $10 Set to Soar: Sportsman's Warehouse and More

Bind Therapeutics (BIND) Highlighted As Weak On High Volume

Why Bind Therapeutics (BIND) Stock Is Down in Pre-Market Trading Today